Can cosmetic procedures become addictive? New study links addiction risk to social media and body image
Peer-Reviewed Publication
Updates every hour. Last Updated: 26-Oct-2026 09:16 ET (26-Oct-2026 13:16 GMT/UTC)
As cosmetic procedures become increasingly normalized worldwide, new research suggests that for some women, repeated treatments may become addiction-like rather than purely cosmetic. The study found that one in five women who had undergone cosmetic procedures met the threshold for moderate-to-severe risk of addictive cosmetic procedure use, with low body esteem and problematic social media use emerging as the strongest risk factors.
A new report in The Lancet Haematology, led by Cleveland Clinic hematologist Bethany Samuelson Bannow, M.D., outlines practical strategies to improve diagnosis, care and outcomes globally for women and girls with hematological conditions, such as bleeding disorders, heavy menstrual bleeding, postpartum hemorrhage, thrombosis and maternal hematologic complications.
The Commission on Global Female Health and Haematology highlights the need for earlier diagnosis, more consistent treatment, and stronger research and education for hematological conditions. Drawing on evidence from clinical care, research, public health and policy, the findings from the Lancet Haematology Commission were presented at the International Society on Thrombosis and Haemostasis (ISTH) 2026 Congress in Paris, France.Experts are calling for a major overhaul of health and aged care systems to cater for rising numbers of elderly people.
As global birth rates decline and life expectancy rises, the World Health Organization (WHO) forecasts the number of people aged 60 and over will double to more than 2 billion by 2050, placing unprecedented pressure on health and aged care systems worldwide.
Shanghai, China, July 13, 2026 – Insilico Medicine (“Insilico”, 03696.HK), a clinical-stage biotechnology company driven by generative artificial intelligence (AI), China Medical System Holdings Limited (“CMS”, 867.HK/8A8.SG), an open-platform innovative company linking pharmaceutical innovation and commercialization with strong product lifecycle management capability, today announced an additional AI‑empowered drug discovery collaboration targeting a mass-market indication in central nervous system with an innovative mechanism of action (MoA) identified by PandaOmics.
A class of man-made chemicals formerly used as flame retardants in a wide range of products continues to pose a significant threat to environmental health.